نتائج البحث - Cristina Encinas Rodriguez

  • يعرض 1 - 1 نتائج من 1
تنقيح النتائج
  1. 1
    Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

    Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refrac... حسب Noffar Bar, María‐Victoria Mateos, Paz Ribas, Markus Hansson, Laura París, Craig C. Hofmeister, Paula Rodríguez‐Otero, Maria Aranzazu Bermúdez, Thomas G Martin, Armando Santoro, Andrew J. Yee, Maria Creignou, Cristina Encinas Rodriguez, Claudio Cerchione, Javier de la Rubia, Albert Oriol, Heidi Waibel, Britta Besemer, Ethan Thompson, Brian F. Kiesel, Jinjie Chen, Alexander Yaw Fui Chung, Isaac W. Boss, Allison Gaudy, Shaoyi Li, Kevin Hsu, Colin D. Godwin, Michael R. Burgess, Jesús F. San Miguel, Luciano J. Costa

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: